RE:A Reminder to Vote NOApostata, "If we merge w/ AEZS then our investment will be swallowed by a shadow company that produces nothing..." As for the truth, AEZS's launch of its diagnostic for growth hormone deficiency in the adult market is accelerating and with the completion of the pediatric clinical trial anticipated at the end of last year upon approval the test could soon be launched into its most important market(children). With clinical trial expenses behind the company AEZS's diagnostic is a potential cashcow complementing CZO's base buisness.
Q3 report:
“We are pleased with the progress made in the last quarter with respect to the commercialization of Ghryvelin™ (macimorelin and previously sold in the United States as Macrilen®) in the European Economic Area (EEA). Following regional pricing approvals, Pharmanovia, our commercialization partner in the EEA, has launched Ghryvelin™ in the UK, Germany, Scandinavia and other countries in the EEA, and is expecting to launch Ghryvelin™ in additional countries in the EEA during the remainder of 2023 and into the first half of 2024. In South Korea, Macrilen® granules received MFDS approval in September so that, together with our partner NK Meditech, we are now preparing to launch Macrilen® in the South Korean market,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna.